BioSpace News Archive

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that its industry-leading team of oncology experts will attend the American Association for Cancer Research (AACR) Annual Meeting.

Solid Biosciences Inc. (Nasdaq: SLDB) today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation for SGT-003, the company’s next-generation Duchenne muscular dystrophy (Duchenne) gene therapy candidate.

Prenetics Global Limited today announced unaudited financial results for the fourth quarter and full year ended December 31, 2023, along with recent business updates.

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, is pleased to announce the launch of its RENASYS EDGE Negative Pressure Wound Therapy (NPWT) System in the US as a patient-centric option for treating chronic wounds.

Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it will present data on etripamil at two upcoming cardiology conferences this month.

Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced its financial results for the twelve months ended December 31, 2023, and provided a clinical and business update.

Aquestive Therapeutics, Inc. today announced the appointment of Abigail Jenkins to the Company’s Board of Directors, effective April 1, 2024.

Vincerx Pharma, Inc. will host a virtual investor event reviewing preliminary clinical data from its Phase 1 dose-escalation study of VIP236 and provide an update on pipeline progress on Monday, April 8, 2024, at 2 PM PT.

CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today reported its financial results for the fourth quarter and full year ended December 31, 2023.

NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, today announced results for the fourth quarter ended December 31, 2023 and provided a business update.